| Aug 12 |
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Aug 12 |
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
|
| Aug 9 |
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Aug 8 |
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
|
| Jul 25 |
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
|
| Jul 25 |
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
| Jul 15 |
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
|
| Jul 15 |
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
|
| Jul 5 |
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
